Levofloxacin (hydrochloride)

Levofloxacin hydrochloride is an orally active antibiotic. Levofloxacin inhibits DNA gyrase and topoisomerase IV activity, inducing Apoptosis. Levofloxacin hydrochloride has antibacterial activity against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride exhibits anticancer activity against lung cancer. Levofloxacin hydrochloride has anti-acnegenic, anxiogenic, and analgesic effects. Levofloxacin hydrochloride shortens sleep duration in mice. Levofloxacin hydrochloride can be used in the research of infectious diseases (such as tuberculosis, chronic periodontitis, bacterial infections associated with stable COPD, and BK viremia) and lung cancer[1][2][3][4][5][6][7][8][9][10].

Product Specifications

CAS Number

[177325-13-2]

Product Name Alternative

(-) -Ofloxacin (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H317, H334, H361, H362

Target

Antibiotic; Apoptosis; Bacterial; DNA/RNA Synthesis; Orthopoxvirus; Topoisomerase

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/levofloxacin-hydrochloride.html

Purity

98.0

Solubility

H2O : 20 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

[H]Cl.O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O

Molecular Formula

C18H21ClFN3O4

Molecular Weight

397.83

Precautions

H302, H317, H334, H361, H362

References & Citations

[1]Drlica K, et al. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61 (3) :377-92.|[2]Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57 (1-2) :41-52.|[3]Rand A, et al. Effect of levofloxacin on some body tissues in mice. Effect of levofloxacin on some body tissues in mice. Iraqi Journal of Veterinary Sciences, 2021. |[4]JI B, et al. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jun;39 (6) :1341-4. |[5]Siva R, et al. Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis. 2014 Feb 7;9:179-86.|[6]Pradeep AR, et al. Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent. 2015 Aug;6 (3) :170-8. |[7]Lee BT, et al. Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial. Clin J Am Soc Nephrol. 2014 Mar;9 (3) :583-9. |[8]Ishida H, et al. In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1998 Jul;42 (7) :1641-5. |[9]Song M, et al. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through inducing mitochondrial dysfunction and oxidative damage. Biomed Pharmacother. 2016 Dec;84:1137-1143. |[10]Erden BF, et al. Antidepressant, anxiogenic, and antinociceptive properties of levofloxacin in rats and mice. Pharmacol Biochem Behav. 2001 Mar;68 (3) :435-41.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

Topoisomerase

Citation 01

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

34070-100μl 100 µL

Anti-Human PSAP Antibody (34070) - 100μl

Ask

View Details

MR210618A1V 250 µL

Mouse Ctnnb1 (BC053065) AAV Particle

Ask

View Details

133293 100 µg

SH2D3C (SH2 Domain-Containing Protein 3C, Novel SH2-Containing Protein 3, NSP3, UNQ272/PRO309/PRO34088)

Ask

View Details

P522961 100 µg

CD47 Protein (C-AVI & His, Human)

Ask

View Details